Ranbaxy launches generic Rocaltrol
RBXLF | Quote | Chart | News | PowerRating -- Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories, has signed an agreement with Validus Pharmaceuticals to market and distribute an authorized generic version of Rocaltrol in both softgel capsules and an oral liquid formulation.
Rocaltrol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure not yet on dialysis, and in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis.
Rocaltrol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypo-parathyroidism.
Ranbaxy will launch the product immediately to all classes of trade in the US market, and expects to be the only generic company offering all forms and strengths of generic Rocaltrol.
Jim Meehan, vice president of sales and distribution for Ranbaxy Pharmaceuticals, said: "Ranbaxy was very pleased to be selected by Validus as their distribution partner for an authorized generic version of Rocaltrol. This product represents an excellent commercial opportunity for Ranbaxy which will increase our visibility and presence in the US healthcare system. We look forward to a long and prosperous partnership with Validus."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
For full details on (RBXLF) RBXLF. (RBXLF) has Short Term PowerRatings at TradingMarkets. Details on (RBXLF) Short Term PowerRatings is available at This Link.
- Syntropharma signs marketing agreement with Ranbaxy Pharmaceuticals for generic transdermal product - 02/02/10
- Ranbaxy launches anti-fungal chemical in India - 01/11/10
- Ranbaxy in talks to acquire Bangalore vaccine co for Rs 50-cr - 01/08/10
- Ranbaxy Laboratories signs license agreement with Summit Pharmaceuticals for Lulifin (Luliconazole) - 01/07/10
- Ranbaxy to transfer stake in Chinese operations to Chembio Pharmacy - 01/07/10
- More News >>


